Base de données sur les brevets canadiens / Sommaire du brevet 2887682 

Énoncé de désistement de responsabilité concernant l'information provenant de tiers

Une partie des informations de ce site Web à été fournie par des sources externes. Le gouvernement du Canada n'assume aucune responsabilité concernant la précision, l'actualité ou la fiabilité des informations fournies par les sources externes. Les utilisateurs qui désirent employer cette information devraient consulter directement la source des informations. Le contenu fournit par les sources externes n'est pas assujetti aux exigences sur les langues officielles, la protection des renseignements personnels et l'accessibilité.

Disponibilité de l'Abrégé et des Revendications

L'apparition de différences dans le texte et l'image des Revendications et de l'Abrégé dépend du moment auquel le document est publié. Les textes des Revendications et de l'Abrégé sont affichés :

  • lorsque la demande peut être examinée par le public;
  • lorsque le brevet est émis (délivrance).
(12) Demande de brevet: (11) CA 2887682
(54) Titre français: POLYTHERAPIES ET LEURS UTILISATIONS POUR LE TRAITEMENT DE TROUBLES DE LA DEMYELINISATION
(54) Titre anglais: COMBINATION THERAPIES AND USES FOR TREATMENT OF DEMYELINATING DISORDERS
(51) Classification internationale des brevets (CIB):
  • A61K 39/395 (2006.01)
  • A61K 39/00 (2006.01)
  • A61P 25/28 (2006.01)
  • C07K 16/28 (2006.01)
(72) Inventeurs (Pays):
  • CADAVID, DIEGO (Etats-Unis d'Amérique)
  • MI, SHA (Etats-Unis d'Amérique)
(73) Titulaires (Pays):
  • BIOGEN MA INC. (Etats-Unis d'Amérique)
(71) Demandeurs (Pays):
  • BIOGEN IDEC MA INC. (Etats-Unis d'Amérique)
(74) Agent: GOWLING WLG (CANADA) LLP
(45) Délivré:
(86) Date de dépôt PCT: 2013-10-08
(87) Date de publication PCT: 2014-04-17
(30) Licence disponible: S.O.
(30) Langue des documents déposés: Anglais

(30) Données de priorité de la demande:
Numéro de la demande Pays Date
61/711,638 Etats-Unis d'Amérique 2012-10-09

Abrégé français

L'invention concerne des procédés et des compositions pour améliorer un ou plusieurs parmi : la myélinisation, la remyélinisation, les nombres d'oligodendrocytes ou la projection neuroaxonale, tout en améliorant l'état inflammatoire chez un sujet humain. Selon certains modes de réalisation, les procédés et compositions décrits ici comprennent un agent réparateur (par exemple un antagoniste de LINGO-1) et un agent immunomodulateur, en combinaison. Par conséquent, les procédés, compositions et trousses décrits ici peuvent être utiles dans le traitement d'une maladie de démyélinisation du SNC.


Abrégé anglais

Methods and compositions for enhancing one or more of: myelination, re-myelination, oligodendrocyte numbers, or neuroaxonal protection, while ameliorating an inflammatory condition in a human subject are disclosed. In certain embodiments, the methods and compositions described herein include a reparative agent (e.g., a LINGO-1 antagonist) and an immunomodulatory agent, in combination. Thus, methods, compositions and kits described herein can be useful for treating a CNS demyelinating disease.


Note : Les revendications sont présentées dans la langue officielle dans laquelle elles ont été soumises.



What is claimed is:
1. A method of treating a CNS demyelinating disease chosen from multiple
sclerosis or an inflammatory condition of the optic nerve, in a subject in
need thereof,
said method comprising administering to the subject an anti-LINGO-1 antibody
molecule
and an immunosuppressive agent in an amount sufficient to treat the CNS
demyelinating
disease, wherein the immunosuppressive agent is chosen from one or more of:
an IFN-.beta. 1 molecule;
a corticosteroid;
a polymer of glutamic acid, lysine, alanine and tyrosine or glatiramer;
an antibody or fragment thereof against alpha-4 integrin or natalizumab;
an anthracenedione molecule or mitoxantrone;
a fingolimod or FTY720 or other SIP1 functional modulator;
a dimethyl fumarate;
an antibody to the alpha subunit of the IL-2 receptor of T cells or
daclizumab;
an antibody against CD52 or alemtuzumab;
an antibody against CD20; or
an inhibitor of a dihydroorotate dehydrogenase or teriflunomide;
thereby treating the CNS demyelinating disease.
2. The method of claim 1, wherein the CNS demyelinating disease is multiple
sclerosis.
3. The method of claim 1, wherein the inflammatory condition of the optic
nerve
is optic neuritis.
4. The method of claim 3, wherein the optic neuritis is acute optic neuritis.
5. A method of treating multiple sclerosis or optic neuritis, in a subject in
need
thereof, said method comprising administering to the subject an anti-LINGO-1
antibody
molecule, and an IFN-.beta. 1 molecule, in an amount sufficient to treat the
multiple sclerosis
or optic neuritis.
-113 -



6. A method of treating multiple sclerosis or optic neuritis, in a subject in
need
thereof, said method comprising administering to the subject an anti-LINGO-1
antibody
molecule and a corticosteroid, in an amount sufficient to treat the multiple
sclerosis or the
optic neuritis.
7. The method of any of claims 1-6, wherein the anti-LINGO-1 antibody molecule

causes one or more of: enhances myelination, enhances neuroaxonal protection,
promotes differentiation and survival of oligodendrocytes, enhances synapse
number or
synapse efficiency, or accelerates conduction velocity.
8. The method of any of claims 1-7, wherein the anti-LINGO-1 antibody
molecule is a monoclonal antibody against human LINGO-1.
9. The method of claim 8, wherein the anti-LINGO-1 antibody molecule is a
human, humanized, a CDR-grafted, or an in vitro-generated antibody against
human
LINGO-1.
10. The method of either of claim 8 or 9, wherein the anti-LINGO-1 antibody
molecule is an immunoglobulin G subclass 1 (IgG1).
11. The method of any of claims 1-10, wherein the anti-LINGO-1 antibody
molecule comprises an aglycosyl (IgG1) framework.
12. The method of any of claims 1-11, wherein the anti-LINGO-1 antibody
molecule is modified to reduce effector cell and complement function compared
to wild-
type IgGl.
13. The method of any of claims 1-12, wherein the anti-LINGO-1 antibody
molecule comprises one, two or three CDRs of a heavy chain variable domain
comprising
-114-



the amino acid sequence of SEQ ID NO: 6, 7 or 8, or SEQ ID NO: 2, 3 or 30, or
a
sequence substantially identical thereto.
14. The method of any of claims 1-12, wherein the anti-LINGO-1 antibody
molecule comprises one, two or three CDRs of a light chain variable domain
comprising
the amino acid sequence of SEQ ID NO: 14, 15 or 16, or SEQ ID NO: 10, 11 or
12, or a
sequence substantially identical thereto.
15. The method of any of claims 1-12, wherein the anti-LINGO-1 antibody
molecule comprises a heavy chain variable domain comprising the amino acid
sequence
of SEQ ID NO: 5 or SEQ ID NO: 66, or a sequence substantially identical
thereto.
16. The method of any of claims 1-12, wherein the anti-LINGO-1 antibody
molecule comprises a light chain variable domain comprising the amino acid
sequence of
SEQ ID NO: 13 or SEQ ID NO: 9, or a sequence substantially identical thereto.
17. The method of any of claims 1-12, wherein the anti-LINGO-1 antibody
molecule comprises a heavy chain comprising the amino acid sequence of SEQ ID
NO:
275, or a sequence substantially identical thereto; and a light chain
comprising the amino
acid sequence of SEQ ID NO: 276, or a sequence substantially identical
thereto.
18. The method of any of claims 1-17, wherein the IFN-.beta. 1 molecule
comprises
one or more of an IFN-.beta. 1a or IFN-.beta. 1b polypeptide, a variant, a
homologue, a fragment
or a pegylated variant thereof.
19. The method of any of claims 1-17, wherein the IFN-.beta. 1 molecule
comprises
an IFN.beta. agent chosen from an IFN-.beta. 1a molecule, an IFN-.beta. 1b
molecule, or a pegylated
variant of an IFN-.beta. 1a molecule or an IFN-.beta. 1b molecule.
20. The method of claim 19, wherein the IFN-.beta. 1a molecule is Avonex®
or
Rebif®; and the IFN.beta.-1b molecule is Betaseron® or Betaferon®
or Extavia®.
-115-




21. The method of any of claims 1-20, wherein the anti-LINGO-1 antibody
molecule comprises a heavy chain variable domain comprising the amino acid
sequence
of SEQ ID NO: 5 or SEQ ID NO: 66, and a light chain variable domain comprising
the
amino acid sequence of SEQ ID NO: 13 or SEQ ID NO: 9; and the
immunosuppressive
agent is Avonex®.
22. The method of any of claims 1-21, wherein the subject has one of:
relapsing-
remitting multiple sclerosis (RRMS), primary progressive MS, secondary
progressive
MS, clinically isolated syndrome (CIS), clinically defined MS (CDMS), or
benign MS.
23. The method of claim 22, wherein the subject has one or more newly
developed lesions.
24. The method of claim 22, wherein the subject has one or more pre-existing
lesion.
25. The method of any of claims 1-21, wherein the subject has relapsing-
remitting multiple sclerosis (RRMS).
26. The method of any of claims 1-21, wherein the subject has secondary
progressive MS (SPMS).
27. The method of claim 25 or 26, wherein the subject is a patient with active

disease.
28. The method of any of claims 1-27, wherein said treating step comprises
reducing one or more symptoms associated with the disease; or reducing
retarding or
preventing, a relapse, or the worsening of a disability, in the subject.
-116-

29. The method of any of claims 1-28, wherein the anti-LINGO-1 antibody
molecule and the immunosuppressive agent are administered concurrently.
30. The method of any of claims 1-28, wherein the anti-LINGO-1 antibody
molecule and the immunosuppressive agent are administered sequentially.
31. The method of any of claims 1-28, wherein the administration of the anti-
LINGO-1 antibody molecule and the immunosuppressive agent overlaps in part
with
each other.
32. The method of any of claims 1-28, wherein initiation of the administration
of
the immunosuppressive agent and the anti-LINGO-1 antibody molecule occurs at
the
same time.
33. The method of any of claims 1-28, wherein the immunosuppressive agent is
administered before initiating treatment with the anti-LINGO-1 antibody
molecule.
34. The method of any of claims 1-28, wherein the anti-LINGO-1 antibody
molecule is administered before initiating treatment with the
immunosuppressive agent.
35. The method of any of claims 1-28, wherein administration of the
immunosuppressive agent continues after cessation of administration of the
anti-LINGO-
0-1 antibody molecule continues after cessation of administration of the
immunosuppressive agent.
37. The method of any of claims 1-36, wherein the anti-LINGO-1 antibody
molecule is an antibody molecule against LINGO-1 and is administered
intravenously,
subcutaneously, intravitreally, intrathecally or intramuscularly.
-117-

38. The method of claim 40, wherein the anti-LINGO-1 antibody molecule is
administered intravenously.
39. The method of any of claims 1-38, wherein the anti-LINGO-1 antibody
molecule is dosed at 1 to 100 mg/kg.
40. The method of any of claims 1-38, wherein the anti-LINGO-1 antibody
molecule is dosed at about 3 mg/kg, about 10 mg/kg, about 30 mg/kg, about
50mg/kg, or
about 100 mg/kg.
41. The method of any of claims 1-40, wherein the anti-LINGO-1 antibody
molecule is administered once every one, two, three, four or five weeks by IV
infusion.
42. The method of any of claims 1-41, wherein the immunosuppressive agent is
an IFN-.beta. 1 molecule is administered intravenously, subcutaneously or
intramuscularly.
43. The method of claim 42, wherein the IFN-.beta. 1 molecule is administered
at
one or more of:
(i) at 20-45 microgram once a week via intramuscular injection;
(ii) at 20-30 microgram three times a week, or at 40-50 micrograms three times
a
week, via subcutaneous injection; or
(iii) in an amount of between 10 and 50 i.ig intramuscularly, three times a
week, or
every five to ten days once a week.
44. The method of any of claims 1-43, wherein:
the anti-LINGO-1 antibody molecule is administered once every four weeks by
IV infusion dosed at about 3 mg/kg, about 10 mg/kg, about 30 mg/kg, about
50mg/kg, or
about 100 mg/kg; and
the immunosuppressive agent is IFN-.beta. 1 and is administered at one or more
of:
(i) at 20-45 microgram once a week via intramuscular injection;
-118-

(ii) at 20-30 microgram once or three times a week, or at 40-50 micrograms
once
or three times a week, via subcutaneous injection; or
(iii) in an amount of between 10 and 50 µg intramuscularly, e.g., three
times a
week, or every five to ten days.
45. The method of any of claims 1-44, wherein the subject has been, or is
being
evaluated by one or more of:
performing a neurological examination;
acquiring the subject's status on the Expanded Disability Status Scale (EDSS);
acquiring the subject's status on the Multiple Sclerosis Functional Composite
(MSFC);
detecting the subject's lesion status;
acquiring a measure of upper and/or lower extremity function;
acquiring a measure of short distance ambulatory function;
acquiring a measure of long distance ambulatory function;
acquiring a measure of cognitive function; or
acquiring a measure of visual function.
46. The method of any of claims 1-44, further comprising one or more of:
acquiring the subject's status on the MSFC;
performing a neurological examination;
acquiring the subject's status on the Expanded Disability Status Scale (EDSS);
detecting the subject's lesion status;
acquiring a measure of upper and/or lower extremity function;
acquiring a measure of short distance ambulatory function;
acquiring a measure of long distance ambulatory function;
acquiring a measure of cognitive function; or
acquiring a measure of visual function.
47. The method of claim 45 or 46, wherein the measure of upper extremity
function is acquired using a 9 Hole Peg Test (9HP).
-119 -

48. The method of claim 45 or 46, wherein the measure of short distance
ambulatory function is acquired using a Timed Walk of 25 Feet (T25FW).
49. The method of claim 45 or 46, wherein the measure of cognitive function
comprises an evaluation of a learning test, a memory test and/or an
attention/processing
speed test.
50. The method of any of claims 1-44, wherein the subject is evaluated using
an
EDSS assessment and an assessment of ambulatory function chosen from one, two,
three,
or all of an assessment of : short distance ambulatory function, long distance
ambulatory
function, upper extremity function or lower extremity function.
51. The method of claim 50, wherein an increase by at least 10%, 15%, 20%,
25% or higher in a measure of extremity and/or ambulatory function is
indicative of
disease progression in the subject; and a decrease of at least 10%, 15%, 20%,
25% or
more in a measure of extremity and/or ambulatory function is indicative of an
improved
outcome in the subject.
52. The method of claim 49, wherein the measure of cognitive function
comprises an evaluation of one or more of auditory memory, verbal learning
and/or
remembering verbal information (e.g., Selective Reminding Test (SRT)); tests
for
evaluating auditory/verbal memory (e.g., California Verbal Learning Test
Second Edition
(CVLT2)), the Rey Auditory Verbal Learning Test (RAVLT); tests for evaluating
visual/spatial memory (e.g., Brief Visuospatial Memory Test Revised (BVMTR));
cognition tests, e.g., PASAT, SDMT; and patient reported outcome measures
(e.g.
MSWS-12, MSIS-29, ABILHAND, MSNQ, and/or SF-36).
53. The method of either of claim 45 or 46, wherein the measure of cognitive
function is performed using a composite of MS cognitive endpoint that
comprises SDMT,
- 120 -

PASAT-3 and -3, SRT-Total Learned (SRT-TL), SRT Delayed Recall (SRT-DR), and
BVMTR Delayed Recall (BVMTR-DR).
54. The method of claim 53, wherein the measure of cognitive function
comprises an MS-COG.
55. The method of any of claims 45-54, wherein an improvement in the subject
is
defined by one or more of:
a. >=1.0 point decrease in EDSS from a baseline score of <=6.0;
b. >=15% improvement from baseline in T25FW;
c. >=15% improvement from baseline in 9HPT; or
d. >=15% improvement from baseline in PASAT.
56. The method of any of claims 45-54, wherein the subject's lesion status is
evaluated using magnetic resonance imaging.
57. The method of claim 56, wherein the magnetic resonance imaging comprises
magnetic transfer and diffusion tensor imaging.
58. A kit comprising an antibody molecule against human LINGO-1 and an IFN-
.beta. 1 molecule with instructions for use in treating multiple sclerosis or
an inflammatory
condition of the optic nerve.
59. A packaged composition comprising an antibody molecule against human
LINGO-1 and an IFN-.beta. 1 molecule with instructions for use in treating
multiple sclerosis
or an inflammatory condition of the optic nerve.
60. A method of treating acute optic neuritis, in a subject in need thereof,
said
method comprising administering to the subject an anti-LINGO-1 antibody
molecule in
an amount sufficient to treat the acute optic neuritis.
- 121 -

61. The method of claim 60, wherein the anti-LINGO-1 antibody molecule
comprises one, two or three CDRs of a heavy chain variable domain comprising
the
amino acid sequence of SEQ ID NO: 6, 7 or 8, or SEQ ID NO: 2, 3 or 30, or a
sequence
substantially identical thereto.
62. The method of claim 60, wherein the anti-LINGO-1 antibody molecule
comprises one, two or three CDRs of a light chain variable domain comprising
the amino
acid sequence of SEQ ID NO: 14, 15 or 16, or SEQ ID NO: 10, 11 or 12, or a
sequence
substantially identical thereto.
63. The method of claim 60, wherein the antibody molecule comprises a heavy
chain variable domain comprising the amino acid sequence of SEQ ID NO: 5 or
SEQ ID
NO: 66, or a sequence substantially identical thereto.
64. The method of claim 60, wherein the antibody molecule comprises a light
chain variable domain comprising the amino acid sequence of SEQ ID NO: 13 or
SEQ ID
NO: 9, or a sequence substantially identical thereto.
65. The method of claim 60, wherein the antibody molecule comprises a heavy
chain comprising the amino acid sequence of SEQ ID NO: 275, or a sequence
substantially identical thereto; and a light chain comprising the amino acid
sequence of
SEQ ID NO: 276, or a sequence substantially identical thereto.
- 122 -


Désolé, le dessin représentatatif concernant le document de brevet no 2887682 est introuvable.

Pour une meilleure compréhension de l’état de la demande ou brevet qui figure sur cette page, la rubrique Mise en garde , et les descriptions de Brevet , États administratifs , Taxes périodiques et Historique des paiements devraient être consultées.

États admin

Titre Date
(86) Date de dépôt PCT 2013-10-08
(87) Date de publication PCT 2014-04-17
(85) Entrée nationale 2015-04-08

Taxes périodiques

Description Date Montant
Dernier paiement 2017-10-04 100,00 $
Prochain paiement si taxe applicable aux petites entités 2018-10-09 100,00 $
Prochain paiement si taxe générale 2018-10-09 200,00 $

Avis : Si le paiement en totalité n’a pas été reçu au plus tard à la date indiquée, une taxe supplémentaire peut être imposée, soit une des taxes suivantes :

  • taxe de rétablissement prévue à l’article 7 de l’annexe II des Règles sur les brevets ;
  • taxe pour paiement en souffrance prévue à l’article 22.1 de l’annexe II des Règles sur les brevets ; ou
  • surtaxe pour paiement en souffrance prévue aux articles 31 et 32 de l’annexe II des Règles sur les brevets.

Historique des paiements

Type de taxes Anniversaire Échéance Montant payé Date payée
Enregistrement de documents 100,00 $ 2015-04-08
Dépôt 400,00 $ 2015-04-08
Taxe périodique - Demande - nouvelle loi 2 2015-10-08 100,00 $ 2015-04-08
Enregistrement de documents 100,00 $ 2015-08-26
Taxe périodique - Demande - nouvelle loi 3 2016-10-11 100,00 $ 2016-09-22
Taxe périodique - Demande - nouvelle loi 4 2017-10-10 100,00 $ 2017-10-04

Pour visionner les fichiers sélectionnés, entrer le code reCAPTCHA :



  • Pour visualiser une image, cliquer sur un lien dans la colonne description du document. Pour télécharger l'image (les images), cliquer l'une ou plusieurs cases à cocher dans la première colonne et ensuite cliquer sur le bouton "Télécharger sélection en format PDF (archive Zip)".
  • Liste des documents de brevet publiés et non publiés sur la BDBC.
  • Si vous avez des difficultés à accéder au contenu, veuillez communiquer avec le Centre de services à la clientèle au 1-866-997-1936, ou envoyer un courriel au Centre de service à la clientèle de l'OPIC.

Filtre Télécharger sélection en format PDF (archive Zip)
Description du
Document
Date
(yyyy-mm-dd)
Nombre de pages Taille de l’image (Ko)
Abrégé 2015-04-08 1 58
Revendications 2015-04-08 10 344
Dessins 2015-04-08 8 784
Description 2015-04-08 113 5 970
Page couverture 2015-04-27 1 31
Poursuite-Amendment 2015-07-06 2 51
PCT 2015-04-08 19 767
Poursuite-Amendment 2015-04-22 2 62

Sélectionner une soumission LSB et cliquer sur le bouton pour télécharger le fichier.

Si vous avez des difficultés à accéder au contenu, veuillez communiquer avec le Centre de services à la clientèle au 1-866-997-1936, ou envoyer un courriel au Centre de service à la clientèle de l'OPIC.

Soyez avisé que les fichiers avec les extensions .pep et .seq qui ont été créés par l'OPIC comme fichier de travail peuvent être incomplets et ne doivent pas être considérés comme étant des communications officielles.

Fichiers LSB

Pour visionner les fichiers sélectionnés, entrer le code reCAPTCHA :